Dossier assessment

Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-31
Last updated

Report documents

  1. Extract of dossier assessment

    Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 312 kB, DE, not accessible
  2. Dossier assessment

    Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-31_V1.1

Drug assessment at a glance

  1. Drug assessment at a glance

    Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 335 kB, EN, not accessible

Dossier assessment

Indication:

Adults with metastatic hormone-sensitive prostate cancer (mHSPC) and breast cancer-associated gene (BRCA)1/2 mutations (germline and/or somatic)

Result of dossier assessment:
  • Patients with newly diagnosed high-risk mHSPC and BRCA1/2 mutations (germline and/or somatic): added benefit not proven
  • All other patients in the therapeutic indication: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

03-09-2026 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A26-31
Commission
Commission awarded on 16.03.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 15.06.2026.

DOI

https://doi.org/10.60584/A26-31_V1.1

Connected Projects

  1. Dossier assessment

    Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-107
    Last updated

    Status: Commission completed

  2. Addendum

    Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A26-31

    Project no.
    A26-98
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form